Abstracts tagged "opioids and pain management"

Abstract Number: 1154 • 2018 ACR/ARHP Annual Meeting
Patterns of Opioid Use and Patient Characteristics before Total Hip and Knee Replacement
Yinzhu Jin¹, Daniel Solomon^1,2, Patricia D. Franklin³, Yvonne C. Lee⁴, Joyce Lii¹, Jeffrey N. Katz⁵ and Seoyoung C. Kim^6,7, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Musculoskeletal Center of Excellence, University of Massachusetts Medical School, Worcester, MA, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with moderate-to-severe hip or knee arthritis often use opioids before undergoing total joint replacement (TJR). Preoperative opioid use may lead to persistent opioid…
Abstract Number: 2221 • 2017 ACR/ARHP Annual Meeting
Eradication of Hepatitis C Among US Veterans: Examination of Changes in Pain Severity and Prescription Opioid Use Following Treatment
Anand Kumthekar¹, Sarah Shull², Benjamin Morasco^3,4, Travis Lovejoy^3,4, Michael Chang² and Jennifer Barton³, ¹Rheumatology, Oregon Health & Science University, Portland, OR, ²Gastroenterology, VA Portland Health Care System, Portland, OR, ³VA Portland Health Care System, Portland, OR, ⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Hepatitis C virus (HCV) is associated with chronic wide spread pain, fatigue, myalgia, arthritis, sicca symptoms and vasculitis. Data regarding prior interferon-based treatment of…
Abstract Number: 2222 • 2017 ACR/ARHP Annual Meeting
Comparative Risk of Respiratory Depression in Patients Treated with Opioids for Non-Malignant Pain
Meghna Jani, Kamilla Kopec-Harding, Mark Lunt and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid use for non-cancer pain has increased considerably over the last 30 years. The U.S. Food and Drug Administration announced several boxed warnings in…
Abstract Number: 2230 • 2017 ACR/ARHP Annual Meeting
Use of Prescription Opioids Among Patients with Systemic Inflammatory Diseases (SID) Versus Patients with Hypertension but No Sid
Sarah Chen¹, Candace H. Feldman², Gregory Brill³, Yvonne C. Lee⁴, Rishi J. Desai⁵ and Seoyoung C. Kim⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham & Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Opioid prescribing in the U.S. has increased at an alarming rate amid uncertainty over effectiveness and rising concerns over safety of this practice. Patients…
Abstract Number: 241 • 2014 ACR/ARHP Annual Meeting
Reduced Estimated Glomerular Filtration Rate Was Improved after Cessation of NSAID and Switching to Tramadol Hydrochloride/Acetaminophen Tablets (Ultracet^TM) in Patients with Chronic Musculoskeletal Pain
Kenji Miki^1,2,3,4, Hiroshi Kajiyama⁵, Kenrin Shi^2,6,7, Shigeshi Mori¹, Masao Yukioka⁸ and Masao Akagi¹, ¹Department of Orthopaedic Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan, ²Center for Pain Management, Osaka University Hospital, Suita, Japan, ³Dept. of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁴Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁵Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ⁶Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ⁸Department of Rheumatology, Yukioka Hospital, Osaka, Japan
Background/Purpose: NSAID is widely used in patients with chronic musculoskeletal pain, but often deteriorates renal function with acute decline of estimated glomerular filtration rate (eGFR).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].